Abbott Laboratories

NYSE:ABT   3:59:57 PM EDT
-0.21 (-0.19%)
4:35:00 PM EDT: $112.49 -0.04 (-0.04%)
Products, Regulatory, Earnings Announcements

Abbott Laboratories Says No Cronobacter Sakazakii Or Salmonella Was Found In Any Of Our Testing Of Products Distributed To Consumers

Published: 03/23/2022 11:48 GMT
Abbott Laboratories (ABT) - Abbott Laboratories - No Cronobacter Sakazakii Or Salmonella Was Found in Any of Our Testing of Products Distributed to Consumers.
Abbott - Genetic Makeup of Cronobacter Sakazakii Microbes in Non-product Areas at Sturgis Facility Did Not Match Cronobacter Sakazakii Microbes From Reported Cases.
Abbott Laboratories - Currently Reviewing U.S. FDA's 483 Observations From Inspection of Co's Powder Formula Manufacturing in Sturgis, Mich.
, Facility.
Abbott Laboratories - Taking Action to Help Address Constraints in Infant Formula Supply.
Abbott Laboratories - Begun Implementing Corrective Actions and Enhancements at Sturgis Facility.
Abbott - Increasing Production of Similac Formulas at Other FDA-registered Facilities.
Abbott - Bringing Similac Advance Into U.S. From an FDA-registered Manufacturing Site in Europe, Including Daily Shipments by Air of Product.
Abbott - Prioritizing Some Production of Other Abbott Liquid Products to Similac & Alimentum to Make More Ready-to-feed Liquid Formula Available.
Abbott Laboratories - Increasing Finished Product Testing, Implementing Auto Sampling Technology in Manufacturing Line at Sturgis Facility.
Further Company Coverage: Abtn ((reuters.
Revenue is expected to be $10.23 Billion
Adjusted EPS is expected to be $1.12

Next Quarter Revenue Guidance is expected to be $9.58 Billion
Next Quarter EPS Guidance is expected to be $0.98

More details on our Analysts Page.